Acer Therapeutics

WKN: A2DYQV ISIN: US00444P1084 Kürzel: P6NA Mehr zu "OPEXA"

Börse
Lang & Schwarz

4,52 EUR

+0,22 % +0,01

Geld (Stk.) 4,440 (1.110)
Brief (Stk.) 4,600 (1.110)
Spread 3,478
Geh. Stück 0 Stk
Eröffnung 4,510
Vortag 4,510
52 Wochen Hoch 26,438
52 Wochen Tief 1,695

Stand: 25.02.2020 - 15:09:48 Uhr

k.A. % HL Intervall: k.A. High: k.A. Low: k.A. Börse: k.A.

k.A. % HL Intervall: k.A. High: k.A. Low: k.A. Kursdaten: k.A.

k.A. % HL Intervall: k.A. High: k.A. Low: k.A. Kursdaten: k.A.

k.A. % HL Intervall: k.A. High: k.A. Low: k.A. Kursdaten: k.A.

k.A. % HL Intervall: k.A. High: k.A. Low: k.A. Kursdaten: k.A.

k.A. % HL Intervall: k.A. High: k.A. Low: k.A. Kursdaten: k.A.

k.A. % HL Intervall: k.A. High: k.A. Low: k.A. Kursdaten: k.A.

k.A. % HL Intervall: k.A. High: k.A. Low: k.A. Kursdaten: k.A.

Anzeige
Alles für nur 4 Euro pro Order. Dauerhaft.
Smartbroker

Geld/Brief Kurse

Börse Geld Brief Zeit Volumen Kurs
Frankfurt 4,440 4,600 1582614945 08:15 0 4,44 EUR
Berlin 20,650 21,600 1582614497 08:08 0 4,42 EUR
Stuttgart 4,240 4,540 1582616130 08:35 0 4,44 EUR
Nasdaq 4,880 4,900 1582592400 02:00 84.151 4,90 USD
AMEX 0,000 0,000 1582578120 24.02.20 100 4,83 USD
Lang & Schwarz 4,440 4,600 1582639788 15:09 0 4,52 EUR

Realtime / Verzögert

Neueste Kommentare (12)

Neu laden

Alle Kommentare Neu laden

Schorsch11

Schorsch11 vom 05.09.19 16:02 Uhr

Acer Therapeutics: Undervalued With A Free Call Option On EDSIVO https://seekingalpha.com/article/4289799-acer-therapeutics-undervalued-free-call-option-edsivo?source=quotemedia_readmore

Schorsch11

Schorsch11 vom 14.08.19 09:32 Uhr

Second Quarter 2019 and Recent Events ACER-001 Investigational New Drug (IND) application cleared for initiation of pivotal bioequivalence bridging and taste assessment trials of ACER-001 compared to sodium phenylbutyrate Disclosed osanetant clinical development plan for patients with induced Vasomotor Symptoms (iVMS), which may include patients receiving tamoxifen treatment for breast cancer and/or leuprolide treatment for prostate cancer and/or women who elect to have prophylactic bilateral oophorectomy (surgical removal of ovaries) where Hormone Replacement Therapy (HRT) is likely contraindicated Ended the second quarter with $23.5 million in cash and cash equivalents, which the Company believes will be sufficient to fund its current operating and capital requirements through the end of 2020 Upcoming Milestones EDSIVO™ Conduct Type A meeting with FDA in Q3 2019 to discuss EDSIVO™ Complete Response Letter ACER-001: Conduct Type C meeting with FDA in 2H 2019 to discuss ACER-001 development plans Initiate ACER-001 pivotal bioequivalence bridging and taste assessment trials in Q4 2019 Submit ACER-001 New Drug Application (NDA) for UCD patients in mid-2020, assuming successful outcomes in bridging trials and sufficient drug product stability data to enable NDA filing Osanetant: Submit osanetant IND in Q4 2019 Initiate Phase 1/2 trial in mid-2020 evaluating osanetant in patients with iVMS, which may include patients receiving tamoxifen treatment for breast cancer and/or leuprolide treatment for prostate cancer and/or women who elect to have prophylactic bilateral oophorectomy (surgical removal of ovaries) where Hormone Replacement Therapy (HRT) is likely contraindicated  http://app.quotemedia.com/quotetools/newsItem.htm?webmasterId=102683&storyId=5960703527122220

Schorsch11

Schorsch11 vom 25.06.19 14:54 Uhr

Mal sehen wie die Amis es aufnehmen: Acer Therapeutics Receives Complete Response Letter from U.S. FDA for use of EDSIVO™ (celiprolol) in vEDS Patients    June 25, 2019 08:30 ET | Source: Acer Therapeutics Inc. NEWTON, Mass., June 25, 2019 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today announced it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for EDSIVO™ for the treatment of vascular Ehlers-Danlos syndrome (vEDS). The CRL states that it will be necessary to conduct an adequate and well-controlled trial to determine whether celiprolol reduces the risk of clinical events in patients with vEDS. Acer plans to request a meeting to discuss the FDA’s response. “We remain committed to working closely with the FDA to fully understand its response,” said Chris Schelling, CEO and Founder of Acer. “We expect to respond to the FDA in the third quarter of this year.” https://www.globenewswire.com/news-release/2019/06/25/1873784/0/en/Acer-Therapeutics-Receives-Complete-Response-Letter-from-U-S-FDA-for-use-of-EDSIVO-celiprolol-in-vEDS-Patients.html

Olli1977

Olli1977 vom 25.04.19 15:57 Uhr

Watch

E

Eppking vom 04.07.17 11:28 Uhr

Sonst noch jemand investiert oder alle schon raus?

E

Eppking vom 04.07.17 11:28 Uhr

www.benzinga.com/content/9680711/acer-therapeutics-and-opexa-therapeutics-sign-merger-agreement

E

Eppking vom 04.07.17 11:27 Uhr

Bin gestern kurzfristig zu 0,93 € rein und schaue mir die Woche mal an was nach der Merger Nachricht noch passiert.

Alle Kommentare Neu laden

Grundlegende Daten zur OPEXA Aktie

Finanzdaten 2016 2017 2018 2019 2020 2021
Ergebnis je Aktie (bereinigt) - - - - - -
Cashflow - - - - - -
Eigenkapitalquote - - - - - -
Verschuldungsgrad - - - - - -
Eigenkapitalrendite - - - - - -
Gesamtkapitalrendite - - - - - -
EBITDA - - - - - -
EBIT - - - - - -
Fundamentaldaten 2016 2017 2018 2019 2020 2021
Dividendenrendite - - - - - -
Kurs-Gewinn-Verhältnis (KGV) - - - - - -
Dividende je Aktie - - - - - -
Bilanzdaten 2016 2017 2018 2019 2020 2021
Netto-Provisionsüberschuss - - - - - -
Umsatzerlöse - - - - - -
Ergebnis vor Steuern - - - - - -
Steuern - - - - - -
Ausschüttungssumme - - - - - -
Nettoverzinsung - - - - - -
Zinsertrag - - - - - -
Gesamtertrag - - - - - -

Acer Therapeutics

Börsennotierung

Marktkapitalisierung
45,53 Mio EUR
Anzahl der Aktien
10,10 Mio Stück